We provide you with 20 years of free, institutional-grade data for CERS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CERS. Explore the full financial landscape of CERS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$748,481
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Jayaraman Vivek K | Sale | -42,359 | $2.94 | $124,658 | 2026-07-02 |
| Jayaraman Vivek K | Grant, award...etc | 474,529 | 2026-07-02 | ||
| Jensen Chrystal | Sale | -24,329 | $2.94 | $71,598 | 2026-07-02 |
| Jensen Chrystal | Grant, award...etc | -55,000 | 2026-07-02 | ||
| Greenman William Mariner | Sale | -101,919 | $2.94 | $299,937 | 2026-07-02 |
| Greenman William Mariner | Grant, award...etc | -192,500 | 2026-07-02 | ||
| Green Kevin Dennis | Sale | -33,676 | $2.94 | $99,105 | 2026-07-02 |
| Green Kevin Dennis | Grant, award...etc | -63,600 | 2026-07-02 | ||
| BJERKHOLT ERIC | Sale | -20,454 | $2.6 | $53,180 | 2026-06-11 |
| BJERKHOLT ERIC | Grant, award...etc | 60,000 | 2026-06-02 | ||
| NACHTSHEIM JAMI K | Grant, award...etc | 60,000 | 2026-06-02 | ||
| Jayaraman Vivek K | Sale | -16,667 | $3 | $50,001 | 2026-06-02 |
| Witney Frank | Grant, award...etc | 60,000 | 2026-06-02 | ||
| Gregory Dean A. | Grant, award...etc | 60,000 | 2026-06-02 | ||
| Shan Hua | Grant, award...etc | 60,000 | 2026-06-02 | ||
| Lucena Ann | Grant, award...etc | 60,000 | 2026-06-02 | ||
| Jayaraman Vivek K | Sale | -16,667 | $3 | $50,001 | 2026-05-05 |
| Jensen Chrystal | Grant, award...etc | 200,000 | 2026-04-03 | ||
| Green Kevin Dennis | Grant, award...etc | 200,000 | 2026-04-03 | ||
| Jensen Chrystal | Sale | -113,008 | $1.66 | $187,277 | 2026-03-16 |
| Jayaraman Vivek K | Sale | -165,200 | $1.66 | $273,769 | 2026-03-16 |
| Greenman William Mariner | Sale | -447,757 | $1.66 | $742,023 | 2026-03-16 |
| Green Kevin Dennis | Sale | -127,544 | $1.66 | $211,366 | 2026-03-16 |
| Benjamin Richard J | Sale | -101,740 | $1.66 | $168,604 | 2026-03-16 |
| Benjamin Richard J | Sale | -125,894 | $2.06 | $259,669 | 2026-03-10 |
| Benjamin Richard J | Grant, award...etc | 55,220 | 2026-03-10 | ||
| Green Kevin Dennis | Sale | -83,021 | $2.06 | $171,231 | 2026-03-09 |
| Green Kevin Dennis | Grant, award...etc | 63,854 | 2026-03-09 | ||
| Benjamin Richard J | Sale | -125,894 | $2.06 | $259,682 | 2026-03-09 |
| Benjamin Richard J | Grant, award...etc | 55,220 | 2026-03-09 | ||
| Jensen Chrystal | Sale | -30,845 | $2.01 | $61,860 | 2026-03-09 |
| Jensen Chrystal | Grant, award...etc | 55,220 | 2026-03-09 | ||
| Jayaraman Vivek K | Sale | -34,094 | $2.01 | $68,376 | 2026-03-09 |
| Jayaraman Vivek K | Grant, award...etc | 80,320 | 2026-03-09 | ||
| Greenman William Mariner | Sale | -78,187 | $2.01 | $156,804 | 2026-03-09 |
| Greenman William Mariner | Grant, award...etc | 193,270 | 2026-03-09 | ||
| Benjamin Richard J | Grant, award...etc | 264,000 | 2026-03-04 | ||
| Green Kevin Dennis | Grant, award...etc | 300,000 | 2026-03-04 | ||
| Greenman William Mariner | Grant, award...etc | 1,200,000 | 2026-03-04 | ||
| Jayaraman Vivek K | Grant, award...etc | 420,000 | 2026-03-04 | ||
| Jensen Chrystal | Sale | -55,000 | $1.7 | $93,500 | 2025-11-26 |
| Gregory Dean A. | Open Market Purchase | 25,000 | $1.25 | 2025-08-25 | |
| NACHTSHEIM JAMI K | Grant, award...etc | 60,000 | 2025-06-04 | ||
| MOORE TIMOTHY L. | Grant, award...etc | 60,000 | 2025-06-04 | ||
| Swisher Daniel N JR | Grant, award...etc | 60,000 | 2025-06-04 | ||
| Lucena Ann | Grant, award...etc | 60,000 | 2025-06-04 | ||
| BJERKHOLT ERIC | Grant, award...etc | 60,000 | 2025-06-04 | ||
| Shan Hua | Grant, award...etc | 60,000 | 2025-06-04 | ||
| Witney Frank | Grant, award...etc | 60,000 | 2025-06-04 |
The information provided in this report about CERS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Cerus Corporation(NASDAQ:CERS) 
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood com...
Website: http://www.cerus.com
Founded: 1991
Full Time Employees: 254
Sector: Healthcare
Industry: Biotechnology